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Summary 
Background: Polycystic ovary syndrome (PCOS) is associat-
ed with reproductive and metabolic abnormalities. The aim
of this study was to analyse risk of cardiovascular disease
(CVD) in PCOS, to define individual risk factors and assess
their ability to predict risk. 
Methods: Fifty-four young women with PCOS (22 obese
and 32 normal weight) were compared to 46 respective
controls (17 obese and 29 normal weight). Anthropometric
parameters, lipid status parameters, inflammation markers,
concentrations of glucose, transaminases, sex and anterior
pituitary hormones, sex hormone binding globulin (SHBG)
and androgens were measured. Cardiovascular Risk Score
(CVRS), indices for identifying Non-Alcoholic Fatty Liver
Disease (NAFLD) and the Index of Central Obesity (ICO)
were calculated.
Results: Significantly higher CVRS values (p<0.05) were
found in obese PCOS women compared to normal weight
control and normal weight PCOS groups. Anthropometric
parameters, lipid status parameters and fibrinogen
(p<0.001, p<0.01) were higher in women with higher
CVRS. The most significant CVRS predictors in all PCOS
women were SHBG, androstenedione, follicle-stimulating
hormone (FSH) and dehydroepiandrosterone sulphate
(DHEAS). ICO and all NAFLD indices exhibited significant
positive correlation with CVRS and a model consisting of
Kratak sadr`aj
Uvod: Sindrom policisti~nih jajnika (PCOS) povezan je sa
reproduktivnim i metaboli~kim abnormalnostima. Cilj ove
studije je bio da se ispita rizik za razvoj kardiovaskularnih
bolesti u sindromu policisti~nih jajnika, da se defini{u poje-
dina~ni faktori rizika i da se proceni njihova sposobnost da
predvide rizik.
Metode: Pedeset ~etiri mlade `ene sa PCOS (22 gojazne i
32 normalno uhranjene) pore|ene su sa 46 ispitanica koje
su ~inile odgovaraju}u kontrolnu grupu (17 gojaznih i 29
normalno uhra njenih). Odre|ivani su antropometrijski
parametri, para metri lipidnog statusa, markeri inflamacije,
koncentracije glukoze, transaminaza, polnih, adeno-
hipofiznih hormona, globulina koji vezuje polne hormone
(SHBG) i androgena. Ra~unati su skor za procenu rizika za
nastanak kardiovaskularnih bolesti (CVRS), indeksi koji se
koriste za dijagnozu nealkoholne masne bolesti jetre
(NAFLD) i indeks centralne gojaznosti (ICO).
Rezultati: Uo~ene su zna~ajno vi{e vrednosti CVRS
(p<0,05) kod gojaznih PCOS `ena u odnosu na normalno
uhranjenu kontrolnu i PCOS grupu. Kod `ena sa vi{im
CVRS utvr|ene su vi{e vrednosti antropometrijskih para-
metara, parametara lipidnog statusa i fibrinogena
(p<0,001, p<0,01). Najva`niji hormonski prediktori rizika
kod svih `ena sa PCOS su bili: SHBG, androstenedion,
folikulostimuliraju}i hormon (FSH) i dehidroepiandros-
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Introduction
Polycystic ovary syndrome (PCOS) is the most
common endocrine disorder in women of reproduc-
tive age with a prevalence of 6 to 20% (depending on
the criteria used for the definition of PCOS), while car-
diovascular disease (CVD) is the most common cause
of death in the world both in women and men (1, 2).
Many studies have demonstrated relationships
between CVD risk factors such as abdominal obesity,
dyslipidemia, glucose intolerance, diabetes and
hypertension and signs of PCOS (3, 4). However, the
existence of risk factors does not mean the same
thing as increased risk. Therefore, the connection
between PCOS and increased risk of developing CVD
is debatable (5). 
Many factors in PCOS, including both metabolic
and hormonal, affect cardiovascular risk (CVR) (6).
Non-alcoholic fatty liver disease (NAFLD) and central
obesity are both risk factors for developing CVD (7).
In addition, NAFLD occurs with an increased inci-
dence in women with PCOS, while central obesity
increases the probability of developing PCOS (8). It is
known that NAFLD is associated with insulin resist-
ance and CVR, but it is not clear whether PCOS and
NAFLD act additively on the CVR. In PCOS, the con-
nection between the CVR and NAFLD and central
obesity can be established using indices for the diag-
nosis of NAFLD (Aspartate aminotransferase to
Platelet Ratio Index, APRI; Hepatic Steatosis Index,
HIS and Lipid Accumulation Product, LAP), as well as
the Index of Central Obesity–ICO (9–12). 
Due to the existence of different criteria to
define PCOS, there are conflicting data on the risk of
CVD in women with PCOS. The aim of this study was
to analyse the risk for CVD in our population. A sec-
ondary aim was to define individual risk factors and
grouped risk factors for developing CVD for their abil-
ity to predict risk.
Materials and Methods
The study included 100 women of similar age
(between 18 and 35 years) who were examined
between January 2007 and December 2007 in the
outpatient department of the Clinic of Internal Me d -
icine at the »Dr Dragisa Misovi}–Dedinje« Clinical
Hospital Centre in Belgrade, after obtaining informed
written consent. The study was approved by the
Institute’s Ethics Committee and conducted respect-
ing the principles set out in the latest amendment to
the Declaration of Helsinki (Edinburgh, 2000). The
women were divided into 2 main groups, a control
group (n=46) and a group with diagnosed PCOS
(n=54). Each group, depending on the nutritional
status, was divided into two subgroups according to
body mass index (BMI): a subgroup of normal weight
women (BMI ≤ 25 kg/m2) and a subgroup of obese
women (BMI > 25 kg/m2).
The control group consisted of 29 healthy nor-
mal weight and 17 obese women. The subjects of the
control group were not taking contraceptives, had
normal glucose metabolism, did not smoke or con-
sume alcohol.
Patients with proven PCOS included 32 normal
weight women and 22 obese women. Diagnosis of
PCOS was determined based on the Rotterdam crite-
ria with exclusion of other causes of hyperandro-
genism, menstrual disorders and infertility (13). None
of the women were taking oral contraceptive therapy,
anti-androgens or drugs that could have affected reg-
ulation of blood pressure, blood lipid and carbohy-
drate metabolism in the previous six months. 
Measurements of body weight and height were
carried out in the morning in a fasting state. Body
mass index (BMI) was calculated based on the
obtained values. The waist circumference (WC) was
measured by a flexible tape measure, simply at the
smallest circumference of the natural waist, usually
just above the belly button, and the hip circumference
was measured at the widest part of the buttocks or
hip. Waist-to-hip ratio (WHR) was calculated using
these values. Upper arm circumference (UAC) is the
circumference of the left upper arm measured at the
mid-point between the tip of the shoulder and the tip
of the elbow. 
these indices provided good diagnostic accuracy (AUC>0.8)
in identifying patients with increased cardiovascular risk
(CVR).
Conclusions: Obesity is a higher risk for developing CVD
than PCOS alone. Anthropometric parameters, lipid param-
eters, fibrinogen, NAFLD indices and ICO increase CVR in
PCOS women. For the prediction of CVR in PCOS, we sug-
gest a combination of NAFLD indices and ICO.
Keywords: polycystic ovary syndrome, cardiovascular dis-
ease, cardiovascular risk score, non-alcoholic fatty liver dis-
ease, central obesity index 
teron-sulfat (DHEAS). ICO i svi NAFLD indeksi su pokazali
zna~ajnu pozitivnu korelaciju sa CVRS, a model sastavljen
od kombinacije ovih indeksa je pokazao dobru dijagno -
sti~ku ta~nost (AUC>0,8) u izdvajanju pacijenata sa povi -
{enim kardiovaskularnim rizikom.
Zaklju~ak: Gojaznost je zna~ajniji rizik za razvoj kardio-
vaskularnih bolesti od samog PCOS. Antropometrijski pa -
rametri, parametri lipidnog statusa, fibrinogen, NAFLD
in deksi i ICO pove}avaju kardiovaskularni rizik kod `ena sa
PCOS. Za procenu kardiovaskularnog rizika u PCOS pred-
la`emo kombinaciju NAFLD indeksa i ICO. 
Klju~ne re~i: sindrom policisti~nih jajnika, kardiovasku-
larne bolesti, procena kardiovaskularnog rizika, nealkoholna
masna bolest jetre, indeks centralne gojaznosti
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Blood samples were collected in the morning in
a fasting state (at least 12 hours after the last meal)
on the second or third day of the menstrual cycle
(except for those women for whom the period
between the two cycles was longer than six weeks, in
this case blood samples were collected after this peri-
od).
The erythrocyte sedimentation rate (ESR) was
determined using a Westergren tube (BD, Plymouth,
UK). The following serum analyses were performed:
transaminases and lipid profile – total cholesterol (TC)
and triglycerides (TG) by standard enzymatic methods
on an Abbott Spectrum chemistry analyser (Abbott
Diagnostics, Illinois, USA). The concentration of high-
density lipoprotein cholesterol (HDL-C) was deter-
mined by the phosphotungstate/magnesium method,
while the concentration of low-density lipoprotein
cholesterol (LDL-C) was determined by the Friede -
wald formula (14). Blood glucose was measured by
the glucose oxidase method on a Beckman glucose
analyser (Beckman Coulter Inc., Brea, USA). Fibri -
nogen was determined by the Clauss method on a
BFT II analyser (Siemens Healthcare GmbH, Ger -
many). Testosterone, sex hormone binding globulin
(SHBG), follicle-stimulating hormone (FSH), luteinis-
ing hormone (LH), estradiol (E2), progesterone,
andro stenedione and dehydroepiandrosterone-sul-
phate (DHEAS) were measured by chemilumines-
cence immunoassays (CLIA) on an Immulite 1000
(Siemens Healthcare GmbH, Germany). LH/FSH
index was determined by calculation. Free Androgen
Index (FAI) was calculated by the formula [(100 ×
total testosterone)/SHBG].
The risk score for the development of cardiovas-
cular disease (CVRS) in young people later in life was
calculated (15) by adding the points for each risk fac-
tor (eg. BMI, low HDL-cholesterol, high non-HDL-
cholesterol, smoking, high blood pressure and fasting
glucose, as well as the age of the patient) (Table I). 
Dyslipidemia existed if there were increased lev-
els of cholesterol (≥ 5.20 mmol/L), triglycerides (≥
1.70 mmol/L), LDL-cholesterol (≥ 3.40 mmol/L), or
if the HDL-cholesterol was decreased (< 1.30
mmol/L). The index of central obesity (ICO) and
NAFLD indices (APRI, HIS and LAP) were calculated
using formulas (Table II).
Statistical analysis was performed using the
Statistical Package for the Social Sciences (version
18.0 for Windows, SPSS Inc., Chicago, IL, USA).
Results are presented as mean ± standard deviation
(⎯x ± SD). Differences between groups were evaluated
by the ANOVA test followed by post hoc Tukey-
Snedecor test. Spearman correlation analyses and
multiple linear regression analyses were also used to
determine the relationships between the determined
parameters. Receiver Operating Characteristic (ROC)
curves were constructed to assess the ability of the
individual parameters and the selected models to pre-
dict cardiovascular risk where CVRS was a dependent
variable. A risk score value greater than 13 (the thre -
shold of the third tertile for this group of women) was
taken as the limit for an increased risk of developing
CVD. P values less than 0.05 were statistically signif-
icant.
Table I Scoring in calculating the risk score for cardiovascu-
lar disease.
Table II Calculation of ICO and NAFLD indices.
Factors Points
Gender (W) -1
non-HDL (mmol/L)
<3.37 0
3.37–4.12 2
4.14–4.90 4
4.92–5.67 6
>5.70 8
HDL (mmol/L)
<1.036 1
1.036–1.530 0
>1.550 -1
Smoking +1
Blood pressure
Normal 0
High 4
Hyperglycemia 5
Age (years)
15–19 0
20–24 5
25–29 10
30–34 15
Indices Calculating formulas Cut-off
ICO WC [cm]/ body height [cm] >0.53
APRI (AST [IU/L]/upper referent range level forAST[IU/L])/ (PLT count [109/L]) × 100 >1.50
LAP (WC [cm] – 58) × (TG [mmol/L]) >54.2
HIS 8 x ALT [IU/L]/AST [IU/L] + BMI (+2points for women,+2 for DM status) >36.0
ICO – index of central obesity, APRI – AST to Platelet Ratio
Index, HIS – Hepatic steatosis Index, LAP – Lipid
Accumulation Product,  ALT – alanine aminotransferase, AST
– aspartate aminotransferase, BMI – body mass index
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Results
The subjects involved in this current study were
divided in four groups according to their obesity sta-
tus and PCOS presence. Anthropometric, biochemi-
cal parameters and hormones that showed significant
difference between these groups of women are pre-
sented in Table III.
After post hoc analyses, the following results
were observed. Normal weight PCOS patients had
significantly lower BMI and WC than obese PCOS
patients. However, their WHR was similar and signifi-
cantly higher than in the normal weight control sub-
jects, although BMI and WC between both normal
weight groups (PCOS patients and control subjects)
were not significantly different. Obese subjects from
both groups had higher values of inflammatory
parameters (ESR and fibrinogen) compared to normal
weight subjects, lower values of HDL-C and elevated
triglyceride concentrations compared to normal
weight subjects, while the concentration of non HDL-
C was highest in obese PCOS patients. Levels of
testosterone, androstenedione, LH and the LH/FSH
ratio were significantly higher in PCOS patients com-
pared to the control group, while the levels of SHBG
and estradiol were significantly lower. 
In order to assess risk for cardiovascular disease
development in later life, we used the CVRS calcula-
tion. The results are presented in Figure 1.
Using ANOVA analysis with Tukey-Snedecor
post hoc test, we found significantly higher CVRS val-
ues in obese PCOS compared to both normal weight
groups (PCOS and CG, p<0.05 respectively). Sig -
nificantly higher CVRS values were found in obese
PCOS patients compared with normal weight PCOS
patients and normal weight control subjects, p<0.05
respectively (using ANOVA/Tukey-Snedecor post hoc
test). According to the results of CVRS calculations,
we then divided our study subjects into CVRS tertiles
(low risk, medium risk and higher risk). We compared
Table III Anthropometric, biochemical parameters and hormones in obese and non-obese women in PCOS and control groups.
Parameter PCOS obese(n=22)
PCOS normal weight
(n=32)
Control group obese
(n=29)
Control group normal
weight (n=17) P
BMI, kg/m2 34.5±5.48 19.9±1.83††† 30.9±4.68†,‡‡‡ 20.9±1.93†††,§§§ <0.001
WC, cm 105.0±15.40 71.0±5.17††† 97.5±10.49‡‡‡ 74.8±7.66†††,§§§ <0.001
UAC, cm 33.7±4.07 23.6±2.08††† 32.9±3.37‡‡‡ 25.8±2.53†††,‡,§§§ <0.001
WHR 0.861±0.079 0.831±0.038 0.828±0.074 0.763±0.059†††,‡‡‡,§§§ <0.001
ESR, mm/h 16.60±9.160 8.91±3.541†† 15.90±10.690‡‡ 9.24±4.830††,§ <0.001
Glucose, mmol/L 4.60±0.530 4.48±0.453 5.13±0.396††,‡‡‡ 4.76±0.368§ <0.001
ALT, IU/L 25.8±12.78 18.1±8.81† 19.9±5.92 16.3±8.53†† <0.01
HDL-C, mmol/L 1.19±0.245 1.53±0.333††† 1.18±0.198‡‡‡ 1.42±0.235††,§ <0.001
non-HDL-C, mmol/L 4.34±1.172 3.33±0.772†† 3.82±1.087 3.52±0.684† <0.01
TG, mmol/L 1.810±0.896 0.931±0.402†† 1.270±0.684† 0.797±0.322†††,§ <0.001
TG/HDL-C 1.640±0.993 0.646±0.348†† 1.120±0.640†,‡ 0.580±0.266†††,§ <0.001
Fibrinogen, g/L 3.69±0.645 2.89±0.561††† 3.45±0.701‡‡ 2.96±0.556††† <0.001
Testosterone, nmol/L 2.35±0.797 2.09±0.714 1.66±0.919† 1.53±0.578††,‡ <0.001
SHBG, nmol/L 38.1±29.58 35.2±10.86 73.1±9.10†††,‡‡‡ 67.3±25.47†††,‡‡‡,§§ <0.001
LH, IU/L 9.51±3.827 9.21±2.867 2.85±1.161†††,‡‡‡ 5.97±3.386††,‡‡‡,§§ <0.001
Estradiol, pmol/L 90.1±44.19 93.5±65.17 124.8±66.17 169.7±95.26††,‡‡‡ <0.001
Androstenedion, ng/mL 3.54±1.380 3.36±0.985 2.09±0.793†††,‡‡‡ 2.01±0.798†††,‡‡‡ <0.001
LH/FSH 1.40±0.493 1.39±0.373 0.47±0.229† 0.79±0.331††,‡ <0.001  
FAI  0.083±0.0518 0.065±0.0282 0.023±0.0118†††,‡‡ 0.273±0.0193 †††,‡‡‡ <0.001  
Dyslipidemia 
no/yes (%) 68.2/31.8 90.6/9.4 64.7/35.3 93.1/6.9
c2=10.3,
<0.05  
BMI – Body mass index; WC – waist circumference; UAC – upper arm circumference; WHR – waist to hip ratio; ESR – erythrocyte
sedimentation rate; ALT – alanine aminotransferase; HDL-C – high-density lipoprotein cholesterol; TG – triglycerides; SHBG – sex
hormone binding globulin; LH – luteinising hormone; E2 – estradiol; LH/FSH ratio; FAI – free androgen index; P from ANOVA
test, followed by post hoc Tukey-Snedecor test
†, ††, ††† – the difference of any group and first group (PCOS obese group)
‡, ‡‡, ‡‡‡ – the difference of the third and/or the fourth group with second group (PCOS normal weight group)
§, §§, §§§ – the difference of the fourth group with the third group (control obese group)
P<0.05, 0.01, 0.001
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other measured parameters that were not included in
CVRS calculations to conclude if CVRS level was
related to other parameters (for example, hormones
measured in PCOS patients). The results are present-
ed in Table IV. We found significantly higher values of
fibrinogen in women with medium CVRS (second ter-
tile) compared with women with low CVRS (first ter-
tile). Anthropometric parameters (except UAC and
WHR), lipid parameters and fibrinogen, which were
not in cluded in CVRS calculation, exhibited signifi-
cantly higher concentrations in women with higher
CVRS compared with women with low or medium
CVRS. In addition, women with higher CVRS did not
differ from those with medium CVRS with respect to
values of UAC, WHR and fibrinogen.
Multiple linear regression analysis was imple-
mented to determine possible influence of hormonal
status of both PCOS groups on CVRS. The initial
model consisted of all measured hormones combined
with backward selection. The analysis revealed the
best models for PCOS patients (Table V).
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Figure 1 CVRS in obese and non-obese PCOS and control
women.
*P<0.05 compared to PCOS overweight or obese women,
according to ANOVA
Table IV Anthropometric, biochemical parameters and hormones according to CVRS tertiles.
Table V Multiple linear regression analysis with CVRS (dependent variable) and measured hormones (independent predictors).
Parameter CVRS Tertiles 
P  
CVRS  range, points First (n=37)0–11
Second (n=39)
11–17
11–17 Third (n=24)
18–24 
WC, cm 78.0±13.35 83.6±17.82 94.3±17.92††,‡ <0.01  
UAC, cm 25.9±4.18 28.3±5.61 30.8±4.89†† <0.01
WHR 0.80±0.065 0.81±0.067 0.85±0.076†† <0.01
AST, U/L 24.6±4.96 25.4±5.54 31.5±11.61††,‡‡ <0.01
TG, mmol/L 0.831±0.308 1.160±0.733 1.600±0.804†††,‡ <0.001
TG/HDL-C 0.592±0.270 0.924±0.663 1.450±0.954†††,‡‡ <0.001
Fibrinogen, g/L 2.88±0.628 3.29±0.706† 3.46±0.553†† <0.01
Dyslipidemia no/yes, % 100/0 87.2/12.8 45.8/54.2 c2 =30.1, P<0.001  
CVRS – cardiovascular risk score; WC – waist circumference; UAC – upper arm circumference; WHR – waist to hip ratio;
TG – triglycerides
P from ANOVA test, followed by post hoc Tukey test
†, ††, ††† – degree of statistical significance found between second or third tertile with first tertile 
‡, ‡‡, ‡‡‡ – degree of statistical significance found between the third tertile with the second tertile 
P<0.05, 0.01, 0.001
PCOS all PCOS obese PCOS normal weight
SHBG 0.025 ( 0.0008–0.0492)* FSH 0.391 (0.022–0.761)* E2 -0.00933 (-0.01721– 0.00145)*
FSH 0.419 (0.168–0.671)** DHEAS 0.000887 (0.0000144–0.001759)*
Androstenedione 0.800 (0.238–1.364)**
DHEAS -0.001 (-0.002– -0.0002)*
Adjusted R2 0.398 0.319 0.460
SHBG – sex hormone binding globulin; FSH – follicle-stimulating hormone, E2 – estradiol, DHEAS – dehydroepiandrosterone-sulfate 
Data show B (CI); *P<0.05, **P<0.01, ***P<0.001 according to MLR analysis
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Figure 2 HIS, APRI, LAP and ICO in the study subgroups.
*P<0.05 compared to PCOS overweight or obese women, according to ANOVA
***P<0.001,**P<0.01 vs. PCOS obese, ##P<0.01,  ###P<0.001 &&& P<0.001 vs. PCOS normal weight.
Figure 3 Correlation between CVRS and NAFLD indices.
Spearman’s non-parametric correlation coefficient r: CVRS with HIS 0.427 (P<0.001), APRI 0.278 (P<0.01), LAP 0.566
(P<0.001), ICO 0.417 (<0.001).
The key CVRS predictors for the whole PCOS
group were SHBG, FSH and androstenedione (posi-
tive correlations) and DHEAS (negative correlation).
The adjusted R2 was 0.398 which indicated that
approximately 40% variability in CVRS values was
related to the selected parameters model. In obese
PCOS women, the most important predictor was only
FSH (positive correlation) (with approximately 30% of
variation). In normal weight PCOS women, the key
predictors were estradiol (negative correlation) and
DHEAS (positive correlation) with approximately 46%
influence on CVRS variability.
In women with PCOS, non-alcoholic fatty liver
disease (NAFLD) is common, which itself is an addi-
tional risk for CVD development. In order to estimate
additional cardiovascular risk, we calculated several
NAFLD indices: APRI, LAP and HIS, as well as the
anthropometric parameter – index of central obesity
(ICO). Figure 2 shows NAFLD scores and ICO in the
study subgroups.
Clearly, HIS, LAP and ICO indices were signifi-
cantly higher in obese PCOS women compared to
other subgroups. In addition, normal weight PCOS
and normal weight control subjects did not differ
regarding these two NAFLD indicies and ICO. No dif-
ferences in the APRI index were found between any
of the subgroups. Spearman's non-parametric corre-
lation between CVRS and NAFLD indices and ICO
are presented in Figure 3. All NAFLD-related param-
eters as well as the ICO index showed significant pos-
itive correlation with CVRS. LAP showed the strongest
correlation with CVRS.
Receiver operating characteristic (ROC) curves
were constructed in order to compare the ability of
LAP, HIS, APRI and ICO indices to predict CVRS
(Figure 4). We compared these parameters using the
area under the curve (AUC) values (Table VI).
According to ROC analysis, LAP was the best predic-
tor for CVRS (Figure 4A, Table VI). Additionally, we
constructed a model consisting of 3 NAFLD indices
(LAP, HIS, APRI) and the anthropometric parameter
ICO using logistic regression analysis-generated pre-
dictive probabilities (Figure 4B). The model showed a
satisfactory diagostic accuracy in discriminating
patients with high CVRS (AUC > 0.8 which was
excellent diagnostic accuracy). 
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Figure 4 A. ROC curve is showing the ability of NAFLD indices and ICO to predict cardiovascular risk, B. ROC curve of model
(integrated ICO, LAP, APRI and HIS indices) to predict cardiovascular risk.
Table VI Area under the curves for NAFLD indices and ICO calculated after constructing ROC curves (Figure 4A) and area under
the curve for model (integrated ICO, LAP, APRI and HIS indices) (Figure 4B).
95% Confidence 
Test Result Variable (s) AUC (SE) Interval P
ICO 0.751 (0.052) 0.648–0.853 <0.001
LAP 0.776 (0.053) 0.673–0.879                              <0.001
HIS 0.757 (0.051) 0.657–0.858 <0.001
APRI 0.757 (0.057) 0.644–0.869 <0.001
Predicted probability – Model 0.815 (0.056) 0.705–0.925 <0.001
AUC – Area Under the Curve; a  Under the non-parametric assumption; b  Null hypothesis: True area = 0.5
Discussion
In order to assess CVD risk in women with
PCOS, we compared the values of measured param-
eters to determine those that were significantly differ-
ent between the examined subgroups. Our results
revealed that obese women had higher anthropomet-
ric measurements and that there was a significant dif-
ference in the levels of hormones in PCOS and
healthy subjects. As expected, women with PCOS in
our study had significantly higher concentrations of
androgens (testosterone, androstenedione) and FAI
and significantly lower concentrations of SHBG com-
pared to control groups (16). Also, LH and the
LH/FSH ratio were significantly higher in both PCOS
groups compared to the control groups. In PCOS, the
secretion of LH is favoured in relation to FSH and this
disorder of gonadotropin secretion, namely an inverse
ratio of FSH to LH, can be seen in 75% of women
with this syndrome (17).
We used a modified risk score (CVRS) (15)
because the classical risk assessment for coronary
heart disease is common practice among the adult
population and evidence for successful implementa-
tion in young adults is not available, except for those
with familial hypercholesterolemia (18). The maxi-
mum number of points in CVRS for women is 24
points. CVRS values greater than 17 indicate that
there is a 20% probability of developing clinically sig-
nificant lesions in the left anterior descending artery
and right coronary artery. Clinically significant lesions
in the left coronary artery are lesions in the fourth and
fifth degree according to the criteria of the American
Heart Association (AHA) (15, 19).
After calculating CVRS and finding that there
was no significant difference in the CVRS between
the two groups of obese patients (PCOS and con-
trols), while the difference was present between the
obese PCOS group and normal weight control group,
the real question was how PCOS could influence car-
diovascular risk and how much influence was from
obesity. Target lesions in the right coronary artery are
those that cover 9% or more of the intimal surface of
the blood vessel (15). Orio et al. (20) noted that
young PCOS women had increased left ventricular
mass and diastolic dysfunction which was not associ-
ated with weight, and suggested that PCOS women
were candidates for development of early CVD.
Bickerton et al. (21) found no significant difference
when criteria for assessing cardiovascular risk using
any of the biochemical parameters that assess the risk
of atherothrombosis or vascular inflammation in
PCOS women were compared to controls matched
according to weight and age. Elting et al. (22)
showed that a higher prevalence of hypertension was
related to obesity, while Chen et al. (23) demonstrat-
ed that hyperandrogenemia in even young women
with PCOS was associated with hypertension inde-
pendently of insulin resistance, BMI and dyslipidemia.
Taking into account these published reports, in our
study we examined the impact of each factor on the
CVRS in both PCOS groups of women as well as the
influence of each factor on increased CVRS. 
We found that women with high CVRS had the
highest WC, UAC and WHR as the greatest risk are
related to obesity. According to the latest guidelines,
increased CVD risk exists in women with PCOS having
any of the following risk factors: obesity, dyslipidemia,
smoking, hypertension, impaired glucose tolerance
and family history of premature CVD (24). In addi-
tion, we found the highest percentage of dyslipidemia
in women with high CVRS. Dyslipidemia is one of the
most common cardiometabolic complications of
PCOS. It occurs in about 70% of patients (25, 17)
and it usually manifests itself in the form of athero-
genic dyslipidemia characterised by hypertriglyc-
eridemia with low concentrations of HDL-C (26). It is
believed that hyperandrogenemia impacts on the
occurrence of dyslipidemia. Namely, it is possible that
androgen excess modifies LDL-C early in life and
leads to a more atherogenic lipid profile (27). In
recent years, a number of studies observed an in -
creased level of LDL in women with PCOS, but there
was considerable variability in the level of LDL, which
was likely due to several factors such as ethnicity, phe-
notype, diet quality and body weight (28). Due to the
influence of hormonal status in PCOS on CVD, mul-
tiple linear regression analysis was performed to
assess impact on the cardiovascular risks of all PCOS
women, normal weight or obese PCOS subjects,
respectively (Table V). Negative correlation between
estradiol and CVRS in the normal weight PCOS group
confirmed that in this group of women estrogen prob-
ably exerted a protective effect on the cardiovascular
system (29, 30). 
FSH positively correlated with CVRS in all PCOS
patients, including obese PCOS patients (Table V). In
pre-menopausal women, the increase in FSH above 7
IU/L was associated with a significant increase in
both total and LDL-cholesterol levels and therefore
with increased cardiovascular risk (31).
Hyperandrogenism is present in women with
PCOS. The relationship between DHEAS and cardio-
vascular risk in PCOS is uncertain. Goodarzi et al. (1)
proposed a DHEAS-mediated protective impact on
the cardiovascular system through an uknown mech-
anism. In addition, Carmina and Lobo found that
PCOS patients with increased DHEAS generally had
more favourable metabolic and cardiovascular
param eters (32). In our study, we confirmed the exis-
tence of negative correlation between CVRS and
DHEAS in all PCOS subjects, while the normal weight
PCOS subjects still showed positive correlation
between DHEAS and CVRS. In contrast, Schaffrath et
al. (33) did not establish a link between the concen-
tration of sex hormones and cardiovascular diseases
using multivariable analysis. The same study also stat-
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ed that, in studies that dealt with PCOS as the primary
problem, SHBG and DHEAS stood out as inversely
associated with subclinical CVD, but these studies
were limited by their cross-sectional nature or only a
small number of women were involved. In contrast,
our study revealed positive correlation between the
concentration of SHBG and CVRS, which cannot be
explained by searching current published literature.
By including NAFLD indices into the study and
relating them to CVRS, we noticed the positioning of
the LAP index as a significant predictor of CVD. This
conclusion is not surprising considering that the LAP
index has proved to be better than BMI for identifying
risk of developing CVD (10). Obese PCOS patients
had an elevated LAP index compared with obese
patients in the control group (Figure 2). The signifi-
cant increase in LAP index in PCOS patients indicated
metabolic disorders in this syndrome (34). The index
of central obesity (ICO) was significantly higher in
obese patients with PCOS compared with all other
study groups (Figure 2). Also, the WHR in normal
weight PCOS women was significantly higher than the
WHR in normal weight control group (although their
BMI is not significantly different) (Table III). Carmina
et al. noted that PCOS women had more abdominal
fat, but similar amounts of total fat, compared with
controls after adjusting for body weight (35). Fat tis-
sue in the abdominal wall and visceral adipose tissue
are metabolically active tissues more sensitive to cat-
echolamines than to insulin. Central obesity is associ-
ated with insulin resistance, glucose intolerance, dia-
betes, an increased production of androgens and
reduced SHBG synthesis. It has been shown that
increased content of abdominal/visceral fat correlates
with cardiometabolic risk factors such as insulin resist-
ance, dyslipidemia, hypertension and metabolic syn-
drome in general (35). This relation with CVD risk
was confirmed through the positive correlation of ICO
index and CVRS (Figure 3). ICO together with NAFLD
indices showed good diagnostic accuracy to segre-
gate patients with increased cardiovascular risk
(Figure 4B, Table VI). Central obesity is a more specif-
ic risk factor for PCOS compared to general obesity.
As the relationship between ICO and CVRS is clear,
ICO links PCOS to cardiovascular risk.
APRI and HIS indices proved to be good predic-
tors of general cardiovascular risk, particularly in com-
bination with LAP and ICO indices (Figure 4, Table
VI). To calculate these indices, aminotransferase lev-
els are used, with the highest level of ALT in obese
PCOS patients (Table III) and the highest level of AST
in the third cardiovascular risk score tertile (Table IV).
APRI is directly proportional to the concentration of
AST which indicates that AST has the ability to predict
cardiovascular risk. Several studies have evaluated the
ability of transaminases to predict cardiovascular risk.
Monami et al. (36) found a correlation between
increased concentrations of AST and in creased risk
for CVD. This indicates that these parameters should
be monitored, as PCOS is a complex disorder with
significant changes in metabolism which can lead to
further damage of the cardiovascular system not pri-
marily caused by the syndrome. Our study indicated
that PCOS did not contribute to a higher risk of devel-
oping CVD compared with obesity but rather demon-
strated the effect of other factors (anthropometric
parameters – WC, lipid parameters – TG, TG/HDL-C,
fibrinogen, NAFLD indices, ICO) on the increase in
cardiovascular risk in women with PCOS. For the pre-
diction of cardiovascular risk in PCOS, our study sug-
gests the combination of NAFLD indices and ICO.
In order to broaden our scientific knowledge
about PCOS, comprehensive syndrome phenotyping
and understanding reproductive and metabolic
abnormalities within phenotypes will require a larger
number of patients and longer follow-up patient mon-
itoring periods.
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